Microfluidics Formulated Liposomes of Hypoxia Activated Prodrug for Treatment of Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) presents as an unmet clinical challenge for drug delivery due to its unique hypoxic biology. Vinblastine-N-Oxide (CPD100) is a hypoxia-activated prodrug (HAP) that selectively converts to its parent compound, vinblastine, a potent cytotoxic agent, under oxygen...

Descripción completa

Detalles Bibliográficos

Autores principales:	Vidhi M. Shah, Craig Dorrell, Adel Al-Fatease, Brittany L. Allen-Petersen, Yeonhee Woo, Yuliya Bortnyak, Rohi Gheewala, Brett C. Sheppard, Rosalie C. Sears, Adam WG. Alani
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	MDPI AG 2022-03-01
Colección:	Pharmaceutics
Materias:	hypoxia-activated prodrug liposome drug delivery organoids pancreatic cancer
Acceso en línea:	https://www.mdpi.com/1999-4923/14/4/713
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!